Patients’ perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population

BMC Cancer

Gunnar Folprecht¹  Gerhard Ehninger¹  Ulrich S Schuler²  Beate Hornemann³  Anke Rentsch¹  Karolin Trautmann⁴  Marika Mende⁴ 

[1]University Cancer Center, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany

[2]Department of Palliative Care, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany

[3]Department of Psychooncology, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany

[4]Medical Department I, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany

关键词: Fatigue;    Survival threshold;    Palliative care;    Chemotherapy;   

Others  :  1079924
DOI  :  10.1186/1471-2407-13-66

 received in 2012-04-23, accepted in 2013-01-30,  发布年份 2013

【 摘 要 】

Background

A better understanding of patients’ views on the benefit and burden obtained from palliative chemotherapy would facilitate shared decision making. We evaluated palliative cancer patients’ reported outcomes (PROs) for toxicity and investigated the survival threshold for which they would repeat chemotherapy (CTx).

Methods

Patients who had received a minimum of three months of palliative CTx for advanced colorectal (CRC) or non-colorectal (non-CRC: upper gastrointestinal, lung and head-and-neck) cancer were assessed by questionnaire. Patients were questioned about PROs for toxicity, subjective burden from side effects, and were asked for the survival threshold necessary for them to repeat CTx. Expected survival (sum of indicated survival threshold and median survival time with best supportive care) was compared to the patients’ actual survival.

Results

One hundred and thirty-four patients (CRC: 58; non-CRC: 76) were surveyed. The most frequent PRO- grade 3/4 toxicities were acne (12.8%), fatigue (9.0%), and diarrhea (8.5%). The symptom causing the highest subjective burden was fatigue and was worse than expected in 29.9% of the patients. The median survival threshold for which patients would repeat CTx was significantly longer in CRC than in non-CRC patients (p=0.01). Median expected survival was significantly longer than actual median survival (CRC: 44.0 months [22.0-65.9] compared with 30.0 months of actual survival [20.9-39.1]; non-CRC: 22.0 months [15.3-28.6] compared with 19.0 months of actual survival [15.1-22.9], p=0.03).

Conclusion

Fatigue deserves more attention when toxicity of treatment and symptoms of disease are explained to patients. Patients’ survival expectations from palliative chemotherapy are higher than previously described, exceed the median survival time known from phase III trials, and are significantly longer than their actual survival.

【 授权许可】

   
2013 Mende et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/ webcite, Assessed on January 26, 2011
• [2]Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al.: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27:3677-3683.
• [3]Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Costenla M, Boni C, et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006, 24:4991-4997.
• [4]Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al.: Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
• [5]Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
• [6]United States Food and Drug Administration: Guidance for industry (draft). Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville (MD): U.S: Department of Health and Human Services; 2006.
• [7]Matsuyama R, Reddy S, Smith TJ: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 2006, 24:3490-3496.
• [8]Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, et al.: Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990, 300:1458-1460.
• [9]Love N, Bylund C, Meropol NJ, Marshall JL, Curley SA, Ellis LM, et al.: How Well Do We Communicate with Patients Concerning Adjuvant Systemic Therapy? A Survey of 150 Colorectal Cancer Survivors. Proceedings of the ASCO Gastrointestinal Cancers Symposium, Abstract No: 239; 2007.
• [10]Balmer CE, Thomas P, Osborne RJ: Who wants second–line, palliative Chemotherapy? Psychooncology 2001, 10:410-418.
• [11]Silvestri G, Pritchard R, Welch HG: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998, 317:771-775.
• [12]Brundage MD, Feldman-Stewart D, Cosby R, Gregg R, Dixon P, Youssef Y, et al.: Cancer patients’ attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support. Patient Educ Couns 2001, 45:149-157.
• [13]Chu DT, Kim SW, Hsu HK, Cok G, Roubec J, Patil S, et al.: Patients attitudes towards chemotherapy and survival: a prospective observational study in advanced non-small cell lung cancer. Lung Cancer 2009, 66:250-256.
• [14]Kim MK, Lee JL, Hyun MS, Do YR, Song HS, Kim JG, et al.: Palliative chemotherapy preferences and factors that influence patient choice in incurable advanced cancer. Jpn J Clin Oncol 2008, 38:64-70.
• [15]Walling A, Lorenz KA, Dy SM, Naeim A, Sanati H, Asch SM, et al.: Evidence-based recommendations for information and care planning in cancer care. J Clin Oncol 2008, 26:3896-3902.
• [16]Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003(http://ctep.cancer.gov webcite), Publish Date: June 10, 2003
• [17]Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995, 61:277-284.
• [18]Sigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
• [19]Bjelland I, Dahl AA, Haug TT, Neckelmann D: The validity of the hospital anxiety and depression scale an updated literature review. J Psychosom Res 2002, 52:69-77.
• [20]Likert R: A technique for the measurement of attitudes. Arch Psych 1932, 140:1-55.
• [21]Group CCC, Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta – analysis. BMJ 2000, 321:531-535.
• [22]Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta - analysis based on aggregate data. J Clin Oncol 2006, 24:2903-2909.
• [23]Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, et al.: Chemotherapy Can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988, 6:633-641.
• [24]Stell PM, Morton RP, Singh SD: Squamous carcinoma of the head and neck: the untreated patient. Clin Otolaryngol Allied Sci 1983, 8:7-13.
• [25]Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
• [26]Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al.: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
• [27]Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
• [28]Narayanan V, Koshy C: Fatigue in cancer: a review of literature. Indian J Palliat Care 2009, 15:19-25.
• [29]Ahlberg K, Ekman T, Gaston-Johansson F, Mock V: Assessment and management of cancer-related fatigue in adults. Lancet 2003, 362:640-650.
• [30]Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al.: Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 2000, 5:353-360.
• [31]Olver IN, Taylor AE, Whitford HS: Relationships between patients’ pre-treatment expectations of toxicities and post chemotherapy experiences. Psychooncology 2005, 14:25-33.
• [32]Sauer H: Basisinformation zum Aufklärungsgespräch Zytostatische Chemotherapie. Erlangen: proCompliance in Thieme GmbH; 2009.
• [33]Brundage MD, Davidson JR, Mackillop WJ: Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997, 15:330-340.
• [34]Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al.: Patient’s expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012, 367:1616-1625.
• [35]Chow E, Andersson L, Wong R, Vachon M, Hruby G, Franssen E, et al.: Patients with advanced cancer: a survey of the understanding of their illness and expectations from palliative radiotherapy for symptomatic metastases. Clin Oncol 2001, 13:204-208.
• [36]Wright AA, Zhang B, Ray A, Mack JW, Trice E, Balboni T, et al.: Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008, 300:1665-1673.
• [37]Mystakidou K, Tsilika E, Parpa E, Athanasouli P, Galanos A, Anna P, Illness-Related Hopelessness in Advanced Cancer, et al.: Influence of anxiety, depression, and preparatory grief. Arch Psychiatr Nurs 2009, 23:138-147.
• [38]Pessin H, Rosenfeld B, Breitbart W: Assessing psychological distress near the end of life. Am Behav Sci 2002, 46:357-372.
• [39]Weis J, Boehncke A: Psychische Komorbidität bei Krebserkrankungen. Bundesgesundheitsbl 2011, 54:46-51.
• [40]Zabora J, Brintzenhofeszoc K, Jacobsen P, Curbow B, Piantadosi S, Hooker C, et al.: A new psychosocial screening instrument for use with cancer patients. Psychosomatics 2001, 42:241-246.
• [41]Smith TJ, Hillner BE: Bending the cost curve in cancer care. NEJM 2011, 364:2060-2065.